# Prevention strategies for hereditary gynaecological cancer in Lynch syndrome

**Authors:** Kevin J. J. Kwinten, Jean-Ellen Johnson, Anne M. van Altena, Nicoline Hoogerbrugge, Emma J. Davidson, Joanne A. de Hullu

PMC · DOI: 10.1007/s10689-026-00548-1 · Familial Cancer · 2026-03-24

## TL;DR

This paper reviews prevention strategies for gynaecological cancers in individuals with Lynch syndrome, focusing on surgical, surveillance, and emerging non-invasive methods.

## Contribution

The paper provides an updated overview of evidence-based prevention strategies and highlights novel approaches for gynaecological cancer prevention in Lynch syndrome.

## Key findings

- Risk-reducing hysterectomy with bilateral salpingo-oophorectomy is the most effective intervention but has significant trade-offs.
- Gynaecological surveillance with transvaginal ultrasound and endometrial biopsy lacks strong evidence for mortality reduction.
- Biomarker-based detection, liquid biopsy, and microbiome profiling show promise but require further validation in Lynch syndrome populations.

## Abstract

Lynch syndrome is a hereditary cancer predisposition condition associated with an elevated lifetime risk of colorectal, endometrial, ovarian, and several other malignancies. This review provides an updated overview of evidence-based prevention strategies for gynaecological cancers in patients with Lynch syndrome. Risk-reducing hysterectomy with bilateral salpingo-oophorectomy is the most effective intervention for lowering cancer incidence and mortality, but is associated with surgical morbidity and requires careful consideration of reproductive plans and the adverse consequences of premature menopause. Gynaecological surveillance using transvaginal ultrasound and endometrial biopsy is widely implemented as an alternative; however, available evidence is heterogeneous and indicates no benefit in reducing mortality. Novel approaches—such as biomarker-based detection using DNA methylation analysis of cervicovaginal samples, liquid biopsy techniques, and microbiome profiling—offer promising, non-invasive alternatives but require prospective validation in Lynch-specific populations. Chemoprevention with hormonal agents and aspirin may reduce cancer risk, while vaccine-based prevention strategies are under active investigation. Adoption of a healthy lifestyle is recommended for overall health, although its impact on gynaecological cancer risk in Lynch syndrome remains uncertain. Future research should prioritise prospective trials to establish optimal cancer prevention protocols, validate novel biomarkers and preventive cancer vaccine strategies, and evaluate the long-term effectiveness, acceptability, and cost-effectiveness of combined preventive approaches to improve outcomes in this high hereditary-risk population.

## Linked entities

- **Diseases:** Lynch syndrome (MONDO:0005835), colorectal cancer (MONDO:0005575), endometrial cancer (MONDO:0002447), ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, RBBP4 (RB binding protein 4, chromatin remodeling factor) [NCBI Gene 5928] {aka NURF55, RBAP48, lin-53}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, ZSCAN12 (zinc finger and SCAN domain containing 12) [NCBI Gene 9753] {aka ZFP96, ZNF29K1, ZNF305, ZNF96, dJ29K1.2}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, GYPC (glycophorin C (Gerbich blood group)) [NCBI Gene 2995] {aka CD236, CD236R, GE, GPC, GPD, GYPD}, MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}
- **Diseases:** microsatellite (MESH:D053842), endometrial cancer (MESH:D016889), premalignant lesions (MESH:D009059), stroke (MESH:D020521), Obesity (MESH:D009765), depression (MESH:D003866), carcinogenesis (MESH:D063646), cardiac disease (MESH:D006331), gastric, duodenal, pancreatic, and urinary tract cancers (MESH:D014571), aneuploidy (MESH:D000782), sexual dysfunction (MESH:D012735), Lynch (MESH:D003123), loss of bone mineral density (MESH:D001851), RRS (MESH:D001523), sleep disturbance (MESH:D012893), mood (MESH:D019964), toxicity (MESH:D064420), pain (MESH:D010146), colorectal polyps or tumours (MESH:D003111), neurocognitive impairment (MESH:D019965), LS (MESH:D015179), EC.N (MESH:C536108), cervical stenosis (MESH:D002575), premature menopause (MESH:D008594), mismatch repair-deficient tumours (MESH:C536928), Lynch syndrome related cancers (MESH:D009369), gPV (MESH:D008881), colorectal, endometrial, ovarian, and several other malignancies (MESH:D045169), endometrial atypia (MESH:D014591), breast cancer (MESH:D001943), autosomal dominantly inherited cancer predisposition (MESH:D009386), atypical endometrial hyperplasia (MESH:D004714), hyperplasia (MESH:D006965), Lynch syndrome-associated ovarian cancer (MESH:D010051), anxiety (MESH:D001007), PL (OMIM:614338), EC (MESH:D005955), vasomotor symptoms (MESH:D012223), colorectal, endometrial, and ovarian cancer (MESH:D018203)
- **Chemicals:** Hormonal agents (-), depot (MESH:C011825), progesterone (MESH:D011374), alcohol (MESH:D000438), estrone (MESH:D004970), estradiol (MESH:D004958), Aspirin (MESH:D001241), Ad5 (MESH:C063004), depo-medroxyprogesterone acetate (MESH:D017258), prostaglandin E2 (MESH:D015232), androstenedione (MESH:D000735), LNG (MESH:D016912)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Lactobacillus (genus) [taxon 1578], Human adenovirus 5 (no rank) [taxon 28285]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013114/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013114/full.md

---
Source: https://tomesphere.com/paper/PMC13013114